INS and Hepatic steatosis: C16 and C18 ceramides are particularly associated with obesity, type 2 diabetes, and liver steatosis, with studies showing that disrupting C18 Cer synthesis improves insulin sensitivity and glucose tolerance in high-fat diet models (44, 45).